Early-Phase Testing of a Measles-Vectored Lassa Fever Vaccine

A live attenuated measles-vectored Lassa fever vaccine was found to be safe and elicited binding, but not neutralizing, antibodies in phase 1 testing.

Lassa hemorrhagic fever is a zoonotic disease caused by the arenavirus Lassa virus (LV) that results in significant morbidity and mortality in West Africa. Currently there are no effective preventive vaccines against Lassa fever. Investigators in Belgium tested the safety, tolerability, and immunogenicity of a live measles-vectored Lassa fever vaccine in 60 healthy adults randomized to low-dose vaccine (LD-MVLV), high-dose vaccine (HD-MVLV), or placebo. The vaccine was given in two doses, 28 days apart. The primary endpoint was the rate of solicited and unsolicited adverse events by day 56.

Solicited and unsolicited adverse events occurred with comparable frequencies in all three groups, except for local side effects (96% of LD-MVLV recipien…

Reviewing Author

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Early-Phase Testing of a Measles-Vectored Lassa Fever Vaccine

Topics

Reviewing Author